[go: up one dir, main page]

TR200100338T2 - Ödem tedavisinde kullanılan TNF-türevleri peptitler. - Google Patents

Ödem tedavisinde kullanılan TNF-türevleri peptitler.

Info

Publication number
TR200100338T2
TR200100338T2 TR2001/00338T TR200100338T TR200100338T2 TR 200100338 T2 TR200100338 T2 TR 200100338T2 TR 2001/00338 T TR2001/00338 T TR 2001/00338T TR 200100338 T TR200100338 T TR 200100338T TR 200100338 T2 TR200100338 T2 TR 200100338T2
Authority
TR
Turkey
Prior art keywords
tnf
edema
alpha
treatment
present
Prior art date
Application number
TR2001/00338T
Other languages
English (en)
Inventor
Lucas Rudolf
Baetseller Patrick
Pugin Jerome
Bloc Alain
Fransen Lucie
Original Assignee
Innogenetics N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innogenetics N.V. filed Critical Innogenetics N.V.
Publication of TR200100338T2 publication Critical patent/TR200100338T2/tr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Mevcut bulus, tümör nekrosit faktör-alfanin (TNF-alfa) bir spesifik alanindan türetilen peptitlerin ödem tedavisinde etkin bir sekilde kullanimina dayanmaktadir. Daha spesifik olarak, mevcut bulus Ser100 den Glu 116 a insan TNF-alfa'sinin bölgesinden türetilen peptitlerin, pulmonar ödemin tedavisinde kullanimina iliskindir. Hatta mevcut bulus, CGQRETPEGAEAKPWYC amino asit sekansi içeren sirkülarize peptitlerinin ödem resorpsyonunu azaltmada çok etkin bulunmaktadir.
TR2001/00338T 1998-08-14 1999-08-10 Ödem tedavisinde kullanılan TNF-türevleri peptitler. TR200100338T2 (tr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP98870180 1998-08-14
EP98870198 1998-09-18
EP98870222 1998-10-21

Publications (1)

Publication Number Publication Date
TR200100338T2 true TR200100338T2 (tr) 2001-12-21

Family

ID=27239778

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/00338T TR200100338T2 (tr) 1998-08-14 1999-08-10 Ödem tedavisinde kullanılan TNF-türevleri peptitler.

Country Status (20)

Country Link
US (2) US20030105021A1 (tr)
EP (3) EP1105152A1 (tr)
JP (1) JP4542266B2 (tr)
CN (1) CN1181886C (tr)
AT (2) ATE395072T1 (tr)
AU (1) AU764992B2 (tr)
BR (1) BR9912899A (tr)
CA (1) CA2334941C (tr)
CZ (1) CZ302862B6 (tr)
DE (2) DE69938743D1 (tr)
DK (1) DK1264599T3 (tr)
ES (1) ES2296872T3 (tr)
HU (1) HU227661B1 (tr)
IL (2) IL141064A0 (tr)
NZ (1) NZ509604A (tr)
PL (1) PL203706B1 (tr)
PT (1) PT1264599E (tr)
TR (1) TR200100338T2 (tr)
WO (1) WO2000009149A1 (tr)
ZA (1) ZA200100656B (tr)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1181886C (zh) 1998-08-14 2004-12-29 基因创新有限公司 Tnf来源的肽在治疗水肿中的应用
ATE457736T1 (de) 2004-08-06 2010-03-15 Nycomed Gmbh Zusammensetzung aus einem pulmonalen surfactant und einem von tnf stammenden peptid
EP2009023A1 (en) * 2007-06-04 2008-12-31 Rentschler Beteiligungs GmbH Novel peptides and their use for the treatment of edema
AT506151B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Fusionsprotein
AT506150B1 (de) 2007-12-12 2010-01-15 Apeptico Forschung Und Entwick Zyklisches und cystein-freies peptid
AT507953B1 (de) * 2009-03-05 2011-02-15 Apeptico Forschung & Entwicklung Gmbh Verfahren zur vermeidung und zur behandlung einer hyperpermeabilität
AT509267A1 (de) 2010-01-14 2011-07-15 Apeptico Forschung & Entwicklung Gmbh Organische verbindungen zur regulierung von vektoriellen ionenkanälen
DK2397151T3 (en) 2010-06-21 2015-05-18 Apeptico Forschung & Entwicklung Gmbh The treatment of the vascular complications of diabetes
US11161881B2 (en) * 2010-11-18 2021-11-02 Apeptico Forschung Und Entwicklung Gmbh Composition comprising a peptide and an inhibitor of viral neuraminidase
AT510585B1 (de) 2010-11-18 2012-05-15 Apeptico Forschung & Entwicklung Gmbh Zusammensetzung umfassend ein peptid und ein hemmstoff der viralen neuraminidase
EP2679239A1 (de) * 2012-06-28 2014-01-01 Apeptico Forschung und Entwicklung GmbH Pharmazeutische Zusammensetzung zur Behandlung der durch Sauerstoffarmut und verringerten Luftdruck vermittelten pulmonalen Form der Höhenkrankheit
US12004506B2 (en) 2013-04-23 2024-06-11 Apeptico Forschung Und Entwicklung Gmbh Pharmaceutical composition comprising a cyclic peptide of formula X1-GQRETPEGAEAKPWY-X2 and use for extracorporeal lung treatment
KR102113501B1 (ko) * 2013-04-23 2020-05-22 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 식 ｘ₁－ｇｑｒｅｔｐｅｇａｅａｋｐｗｙ－ｘ₂의 고리 펩티드를 포함하는 제약 조성물 및 체외 폐 치료를 위한 사용
KR102316762B1 (ko) 2014-03-18 2021-10-26 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 건조 분말 펩티드 약제
CN110613838A (zh) * 2018-06-19 2019-12-27 姜石松 增强细胞通透性的多肽及其应用
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR20230008844A (ko) 2020-05-08 2023-01-16 아펩티코 포어슝 운트 엔트빅크룽 게엠베하 Covid-19의 예방 또는 치료를 위한 펩티드

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE384179C (de) * 1921-04-07 1923-10-27 Ludwig Weil Dr Laufrad fuer Kreiselpumpen und -geblaese
DE3841759A1 (de) 1988-12-12 1990-06-13 Basf Ag Neue tnf-peptide
AU6001094A (en) * 1993-02-03 1994-08-29 N.V. Innogenetics S.A. Tnf-alpha muteins and a process for preparing them
CN1181886C (zh) 1998-08-14 2004-12-29 基因创新有限公司 Tnf来源的肽在治疗水肿中的应用

Also Published As

Publication number Publication date
DE69937206D1 (de) 2007-11-08
CA2334941C (en) 2011-08-09
NZ509604A (en) 2003-05-30
PL203706B1 (pl) 2009-11-30
HUP0103117A3 (en) 2004-03-01
ATE395072T1 (de) 2008-05-15
EP1105152A1 (en) 2001-06-13
PL345997A1 (en) 2002-01-14
JP4542266B2 (ja) 2010-09-08
EP1264599B1 (en) 2007-09-26
HK1051805A1 (en) 2003-08-22
HU227661B1 (hu) 2011-10-28
IL141064A0 (en) 2002-02-10
CN1181886C (zh) 2004-12-29
WO2000009149A1 (en) 2000-02-24
EP1247531B1 (en) 2008-05-14
BR9912899A (pt) 2001-05-08
CA2334941A1 (en) 2000-02-24
US7258861B2 (en) 2007-08-21
US20030185791A1 (en) 2003-10-02
EP1264599A1 (en) 2002-12-11
US20030105021A1 (en) 2003-06-05
JP2002522508A (ja) 2002-07-23
ATE374039T1 (de) 2007-10-15
IL141064A (en) 2009-09-01
CZ2001538A3 (cs) 2001-08-15
DE69938743D1 (de) 2008-06-26
PT1264599E (pt) 2008-01-07
AU5620999A (en) 2000-03-06
AU764992B2 (en) 2003-09-04
CN1312724A (zh) 2001-09-12
DK1264599T3 (da) 2008-02-04
HUP0103117A2 (hu) 2001-12-28
EP1247531A3 (en) 2002-12-18
CZ302862B6 (cs) 2011-12-21
ZA200100656B (en) 2005-06-29
ES2296872T3 (es) 2008-05-01
DE69937206T2 (de) 2008-06-19
EP1247531A2 (en) 2002-10-09

Similar Documents

Publication Publication Date Title
TR200100338T2 (tr) Ödem tedavisinde kullanılan TNF-türevleri peptitler.
DK1337157T3 (da) Proteinhydrolysater
ES2160485A1 (es) Peptidos inhibidores de la exorcitosis neuronal, composiciones cosmeticas y farmaceuticas que los contienen.
CY1107668T1 (el) Χρηση αμινοξικων αντισπασμωδικων για τη θεραπευτικη αγωγη του πονου
IL161591A (en) Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells
NZ333609A (en) Peptide inhibitors of the interaction between P35 and MDM2 and the treatment of tumor cells
EA200000933A1 (ru) Пептидные композиции и препараты и их применение
GEP20043407B (en) Method of Inhibiting Amyloid Protein Aggregation and Imaging Amyloid Deposits Using Isoindoline Derivatives
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
DE60217326D1 (de) Von neurofilamentproteinen abgeleitete peptide und deren medizinische verwendung
BR0012418A (pt) Derivados de peptìdeo cìclicos como inibidores de integrina alfavbeta6
ATE427320T1 (de) Behandlung von infektionen verursacht von mikroorganismen
TW326395B (en) Water-based hair treatment composition as heat-safe preparation and method of using same
DE69329899D1 (de) Behandlung von tropikalischer spastischer Paresis mit Peptide T
DE69330268D1 (de) Hämoregulierende peptide
DE60104695D1 (de) Zusammensetzungen aus aminosäuren zur behandlung von herzinsuffizienz
FI20012082A0 (fi) Biologisesti aktiiviset peptidit hermovauroiden korjaamiseksi
DE60008749D1 (de) Therapeutische peptide aus untersequenzen von bpi
ATE346862T1 (de) Aus pflanzen gewonnene peptide mit wasserreinigender und antimikrobieller wirkung
ATE480560T1 (de) Zusammensetzung zur behandlung von periodontalen erkrankungen